Research on Curcumin and Its Potential Role in Inhibiting Cancer Cell Proliferation
Research on curcumin, a bioactive compound found in turmeric (Curcuma longa), has been extensively investigated through in vitro studies, in vivo animal studies, and early-stage clinical trials.
Examples of Important Research by Level of Evidence
1. In Vitro and Animal Studies
Colorectal Cancer:
A study published in Cancer Letters reported that curcumin can inhibit the NF-κB signaling pathway, which plays an important role in cancer cell growth and survival. This inhibition may lead to cell-cycle arrest and induction of apoptosis in colorectal cancer cells.
Breast Cancer:
A study published in Oncogene reported that curcumin may reduce the expression of genes involved in cancer progression and metastasis. It may also inhibit angiogenesis, the formation of new blood vessels that tumors require to obtain oxygen and nutrients to support cancer cell growth.
2. Human Clinical Trials
Adjunctive Treatment in Patients with Pancreatic Cancer Study:
Dhillon et al., in a study published in Clinical Cancer Research, conducted a Phase II clinical trial involving 25 patients with advanced pancreatic cancer. Participants received curcumin at a dose of 8 g per day.
Findings:
Curcumin was generally well tolerated, with an acceptable safety profile. A small number of patients experienced disease stabilization, and reductions in certain inflammatory biomarkers were also observed.
Potential Enhancement of Chemotherapy in Patients with Colorectal Cancer
Study:
Howells et al., in a study published in Cancer Chemotherapy and Pharmacology, investigated the use of curcumin in combination with the FOLFOX chemotherapy regimen in patients with colorectal cancer.
Findings:
The addition of curcumin to chemotherapy was reported to be well tolerated and showed potential to enhance the anticancer effects of chemotherapy compared with chemotherapy alone. However, further clinical studies are needed to establish the clinical significance and efficacy of this combination.
Important Limitations of Curcumin
Low Bioavailability
Curcumin has poor water solubility and undergoes extensive and rapid metabolism in the liver and intestinal tract. As a result, only a relatively small amount reaches the systemic circulation in its active form. Consequently, various approaches have been developed to improve its bioavailability, including nanoparticle-based formulations and combination with piperine, a bioactive compound found in black pepper.
Curcumin Cannot Currently Replace Standard Cancer Treatment
Although promising anticancer effects have been demonstrated in laboratory and preclinical studies, biological activity observed in vitro does not necessarily translate into equivalent therapeutic effects in humans. Cancer treatment involves complex biological processes, and the clinical efficacy of curcumin remains under investigation.
Therefore, curcumin should currently be considered a potential adjunctive or supportive intervention, rather than a replacement for established standard cancer treatments. It should not be used as a primary treatment for cancer or as a substitute for therapies recommended by qualified healthcare professionals.
Curcumin as tumor suppressor and it's mechanism of action.
Figure 1 illustrates tumor cascade pathways initiated by various growth factors in cancerous cells and anti-Tumorigenic effects stimulate by curcumin on signal transducing elements.
Curcumin in conjugated form target at infected site and down-regulate the expression of PI3K, AKt, NP-κB, MAPK, MAPK, and ROS tumor inducing pathways.
Further inhibit the expression of p21 and p27 cyclin-dependent kinase inhibitors and mitotic effects inhibit by curcumin as a result cycle arrest and down-regulate the expression of various gene products which involved in the cell growth, proliferation and expand of cancer.
เคอร์คูมินในฐานะสารยับยั้งเนื้องอกและกลไกการออกฤทธิ์
รูปที่ 1 แสดงให้เห็นถึงเส้นทางการเกิดเนื้องอกที่เริ่มต้นโดยปัจจัยการเจริญเติบโตต่างๆ ในเซลล์มะเร็ง และผลต้านการเกิดเนื้องอกที่กระตุ้นโดยเคอร์คูมินต่อองค์ประกอบการส่งสัญญาณ
เคอร์คูมินในรูปแบบคอนจูเกต จะมุ่งเป้าไปที่บริเวณที่ติดเชื้อและลดการแสดงออกของ PI3K, AKt, NP-κB, MAPK และ ROS ซึ่งเป็นเส้นทางการกระตุ้นการเกิดเนื้องอก
นอกจากนี้ยังยับยั้งการแสดงออกของ p21 และ p27 ซึ่งเป็นสารยับยั้งไคเนสที่ขึ้นอยู่กับไซคลิน และยับยั้งผลกระทบต่อการแบ่งเซลล์โดยเคอร์คูมิน ส่งผลให้เกิดการหยุดวงจรการแบ่งเซลล์และลดการแสดงออกของผลิตภัณฑ์ยีนต่างๆ ที่เกี่ยวข้องกับการเจริญเติบโต การแพร่กระจาย และการขยายตัวของเซลล์มะเร็ง